Search

Your search keyword '"Turcant, Alain"' showing total 160 results
Start Over Author "Turcant, Alain"
160 results on '"Turcant, Alain"'

1. Trends in fatal poisoning among medical users of analgesics in France from 2013 to 2022: an analysis of the DTA register

Author

Abbara, Chadi, Allorge, Delphine, Alvarez, Jean-Claude, Ameline, Alice, Barret, Anne, Berland, Emilie, Bertin, Célian, Besnard, Thierry, Bevalot, Fabien, Billet-Chatenay, Camille, Boucher, Alexandra, Bouquet, Emilie, Bourgine, Joanna, Brunet, Bertrand, Caous, Anne-Sylvie, Cesbron, Alexandre, Charuel, Lauriane, Cheze, Marjorie, Citterio-Quentin, Antony, Collon-Fabie, Philippe, Dailly, Eric, Daveluy, Amélie, Deffontaine, Grégory, Delage, Martine, Delavenne, Xavier, Descamps, Florence, Descoeur, Juliette, Deslandes, Guillaume, Deveaux, Marc, Devos, Bernadette, Doche, Christophe, Eiden, Céline, Fouley, Aurélie, Gaillard, Yvan, Gambier, Nicolas, Ganière, Catherine, Gérardin, Marie, Goullé, Jean-Pierre, Guerard, Pascal, Hoizey, Guillaume, Humbert, Luc, Imbert, Laurent, Kergueris, Marie-France, Kintz, Pascal, Klinzig, Florian, Labat-Deveaux, Laurence, Lacarelle, Bruno, Lacroix, Christian, Lamiable, Denis, Lavit, Michel, Le Boisselier, Reynald, Le Bouil, Anne, Le Meur, Catherine, Lefeuvre, Sandrine, Lelièvre, Bénédicte, Lelong-Boulouard, Véronique, Lemaire-Hurtel, Anne-Sophie, Loilier, Magalie, Lopez, Vincent, Martin-Molins, Claire, Marty, Hélène, Mathieu, Olivier, Mathieu-Daudé, Jean-Claude, Mauras, Yves, Milan, Nathalie, Moal, Aurélie, Morel, Isabelle, Mura, Patrick, Pelissier-Alicot, Anne-Laure, Pépin, Gilbert, Perrin, Martine, Peyre, Anne, Pineau, Alain, Pochard, Liselotte, Pok, Rop, Ragoucy-Sengler, Catherine, Rayer, Raphaël, Redjimi, Nassima, Roman, Emilie, Roussel, Carine, Sabini, Sandrine, Saussereau, Elodie, Scala-Bertola, Julien, Sibille, Pauline, Spadari, Michel, Thiery, Johan, Titier, Karine, Turcant, Alain, Vacher, Pierrick, Venisse, Nicolas, Vieira, Ophélie, Visinoni, Pascale, Revol, B., Willeman, T., Manceau, M., Dumestre-Toulet, V., Gaulier, J.-M., Eysseric-Guérin, H., and Fouilhé Sam-Laï, N.

Published
2024
Full Text
View/download PDF

14. Cardiogenic shock and status epilepticus after massive bupropion overdose

Author

Morazin, Florian, Lumbroso, Agnes, Harry, Patrick, Blaise, Marcel, Turcant, Alain, Montravers, Philippe, and Gauzit, Remy

Subjects
Bupropion -- Dosage and administration, Bupropion -- Complications and side effects, Cardiogenic shock -- Causes of, Cardiogenic shock -- Case studies, Cardiogenic shock -- Care and treatment, Status epilepticus -- Causes of, Status epilepticus -- Case studies, Status epilepticus -- Care and treatment, Drugs -- Overdose, Drugs -- Care and treatment, Environmental issues, Health, Pharmaceuticals and cosmetics industries
Published
2007

16. 4-methylpyrazole and hemodialysis in ethylene glycol poisoning

Author

Jobard, Eric, Harry, Patrick, Turcant, Alain, Roy, Pierre Marie, and Allain, Pierre

Subjects
Glycols -- Health aspects, Hemodialysis -- Health aspects, Antidotes -- Usage, Environmental issues, Health, Pharmaceuticals and cosmetics industries
Abstract

Case Reports: Two patients severely intoxicated with ethylene glycol became anuric and were treated by hemodialysis and the antidote, 4-methylpyrazole. On admission, their plasma ethylene glycol concentrations were 0.42 and 3 g/L respectively and no alcohol was detected. The elimination of 4-methylpyrazole in the dialysate represented 45% of the total body elimination. Clearances of 4-methylpyrazole by hemodialysis were 80 mL/min and 52 mL/min respectively. Results: In such cases, the authors propose infusion of a 4-methylpyrazole loading dose of 10-20 mg/kg before dialysis and intravenous infusion of 1-1.5 mg/kg/h during the 8-12 hours of hemodialysis to compensate the loss in dialysate., INTRODUCTION Ethylene glycol (EG) poisoning is usually treated by a combination of ethanol and hemodialysis[1,2] 4-Methylpyrazole (4-MP) is a recently used competitive inhibitor of alcohol dehydrogenase and is able to [...]

Published
1996

18. A 6-year review of new psychoactive substances at the Centre antipoison Grand-Ouest d’Angers: Clinical and biological data

Author

Turcant, Alain, primary, Deguigne, Marie, additional, Ferec, Séverine, additional, Bruneau, Chloé, additional, Leborgne, Isabelle, additional, Lelievre, Bénédicte, additional, Gegu, Clément, additional, Jegou, Florence, additional, Abbara, Chadi, additional, Le Roux, Gaël, additional, and Boels, David, additional

Published
2017
Full Text
View/download PDF

21. Voriconazole pharmacokinetics in experimental models of disseminated scedosporiosis: Effect of infection and cyclosporine dosing regimen on voriconazole disposition

Author

Lelièvre, Bénédicte, Abbara, Chadi, Chao de La Barca, Juan Manuel, Godon, Charlotte, Legras, Pierre, Turcant, Alain, Bouchara, Jean-Philippe, Diquet, Bertrand, Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), Université d'Angers (UA), Biologie Neurovasculaire et Mitochondriale Intégrée (BNMI), and Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

National audience

Published
2015

23. Parachuting: a dangerous trend in recreational psychoactive substance delivery

Author

Boels, David, primary, Grall-Bronnec, Marie, additional, Guerlais, Marylène, additional, Le Roux, Gael, additional, Spiers, Andrew, additional, Gerardin, Marie, additional, Lomenech, Hélène, additional, Bretaudeau-Deguigne, Marie, additional, Daveluy, Amélie, additional, Turcant, Alain, additional, Jolliet, Pascale, additional, and Victorri-Vigneau, Caroline, additional

Published
2016
Full Text
View/download PDF

26. Severe serotoninergic syndrome after ingestion of α-methyltryptamine

Author

Férec, Séverine, primary, Leborgne, Isabelle, additional, Bruneau, Chloé, additional, Bourgine, Joanna, additional, Valette, Xavier, additional, Abbara, Chadi, additional, Lelièvre, Bénédicte, additional, Boels, David, additional, Bretaudeau-Deguigne, Marie, additional, and Turcant, Alain, additional

Published
2016
Full Text
View/download PDF

29. Deux cas d’intoxication par le T61®

Author

Lelièvre, Bénédicte, primary, Benâtre, Harmony, additional, Boels, David, additional, Bretaudeau, Marie, additional, Abbara, Chadi, additional, Gégu, Clément, additional, Bruneau, Chloé, additional, Turcant, Alain, additional, and Diquet, Bertrand, additional

Published
2015
Full Text
View/download PDF

30. Erratum to “Acute combined poisoning with the new designer drug 4-methyl-N-ethyl-cathinone (4-MEC) and gammabutyrolactone (GBL): A case report with different analytical approaches for identification of some metabolites” [Toxicol. Anal. Clin. 26 (2014) 119–27]

Author

Turcant, Alain, primary, Boels, David, additional, Helfer, Andreas G., additional, Ferec, Séverine, additional, Bretaudeau-Deguigne, Marie, additional, Lelièvre, Bénédicte, additional, Meyer, Markus R., additional, and Maurer, Hans H., additional

Published
2015
Full Text
View/download PDF

32. Dosage de la metformine par chromatographie liquide en mode Hilic couplée à la spectrométrie de masse en tandem: application à 5 cas d'acidose lactique

Author

Férec, Séverine, Lelièvre, Bénédicte, Lagarce, Laurence, Bretaudeau, M., Turcant, Alain, Diquet, Bertrand, Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), Université d'Angers (UA), Département de Pharmacologie-Toxicologie [CHU Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), and PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

National audience

Published
2010

33. Pharmacokinetic analysis of pralidoxime after its intramuscular injection alone or in combination with atropine-avizafone in healthy volunteers

Author

Abbara, Chadi, Rousseau, J.-M., Lelièvre, Bénédicte, Turcant, Alain, Lallement, Guy, Férec, Séverine, Bardot, Isabelle, Diquet, Bertrand, Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), and Université d'Angers (UA)

Subjects
neurotoxic agents, Pralidoxime, [SDV]Life Sciences [q-bio], Pharmacokinetics, bioavailability
Abstract

International audience; BACKGROUND AND PURPOSETreatment of organophosphate poisoning with pralidoxime needs to be improved. Here we have studied the pharmacokinetics of pralidoxime after its intramuscular injection alone or in combination with avizafone and atropine using an auto-injector device.EXPERIMENTAL APPROACHThe study was conducted in an open, randomized, single-dose, two-way, cross-over design. At each period, each subject received either intramuscular injections of pralidoxime (700mg), or two injections of the combination: pralidoxime (350mg), atropine (2mg), avizafone (20mg). Pralidoxime concentrations were quantified using a validated LC/MS-MS method. Two approaches were used to analyse these data: (i) a non-compartmental approach; and (ii) a compartmental modelling approach.KEY RESULTSThe injection of pralidoxime combination with atropine and avizafone provided a higher pralidoxime maximal concentration than that obtained after the injection of pralidoxime alone (out of bioequivalence range), while pralidoxime AUC values were equivalent. Pralidoxime concentrations reached their maximal value earlier after the injection of the combination. According to Akaike and to goodness of fit criteria, the best model describing the pharmacokinetics of pralidoxime was a two-compartment with a zero-order absorption model. When avizafone and atropine were injected with pralidoxime, the best model describing pralidoxime pharmacokinetics becomes a two-compartment with a first-order absorption model.CONCLUSIONS AND IMPLICATIONSThe two approaches, non-compartmental and compartmental, showed that the administration of avizafone and atropine with pralidoxime results in a faster absorption into the general circulation and higher maximal concentrations, compared with the administration of pralidoxime alone.

Published
2010

34. Intoxications aiguës par le pentobarbital: un vieux produit toujours d'actualité

Author

Turcant, Alain, Lelièvre, Bénédicte, Boels, David, Lagarce, Laurence, Diquet, Bertrand, Cano, Y., Rodrigues-Monteiro, A., Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), Université d'Angers (UA), Département de Pharmacologie-Toxicologie [CHU Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), and PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM)

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

National audience

Published
2010

35. Mise au point du dosage du strontium dans l'eau et le sang: comparaison de deux techniques (ICP-AES, ICP-MS) et application en cas de noyade

Author

Huby, A., Lelièvre, Bénédicte, Mauras, Y., Le Bouil, Anne, Rougé-Maillart, Clotilde, Diquet, Bertrand, Turcant, Alain, Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), Université d'Angers (UA), and Centre Jean Bodin : Recherche Juridique et Politique (CJB)

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

National audience

Published
2010

36. Pharmacokinetics of secnidazole in healthy volunteers after single oral dose

Author

Lelièvre, Bénédicte, Abbara, Chadi, Férec, Séverine, Turcant, Alain, Diquet, Bertrand, Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), and Université d'Angers (UA)

Subjects
[SDV]Life Sciences [q-bio]
Abstract

Résumé publié dans : Fundamental & Clinical Pharmacology, avril 2010, 24(Suppl. 1): p. 55-56. doi:10.1111/j.1472-8206.2010.00819.x; National audience; Introduction: Secnidazole is an anti infective agent which belongs to the 5-nitroimidazole class.Method: The objective of the trial was to characterize the pharmacokinetics of secnidazole after oral administration of a 2g dose, as microgranules formulation in healthy subjects. Blood samples were collected before, 1, 2, 3, 6, 9, 12, 24, 36, 48, 72, 96, 120, 168 and 240 h after dosing. Urines were collected in 24-h-fractions for the first five days and in 48 h-fraction for the last sample. The cumulative urinary excretion was captured for each subject from urine concentration (lg/L). Pharmacokinetic parameters were obtained by a non-compartmental approach (WinNonlin Pharsight). The assay was performed by ultra-performance liquid chromatography coupled with mass spectrometry detection (UPLC-MS/MS, Quattro Premier, Waters) after simple protein precipitation of 50 lL plasma sample. Chromatographic separation was done on a C18 Acquity column (50 mm · 2.1 mm, id 1.7 lm, Waters), in isocratic mode (80% water/0.1% formic acid and 20% acetonitrile). Ornidazole was used as internal standard. The detection was operated in positive mode and multiple reaction monitoring was used for quantification (186 > 128 ion transition for secnidazole). The lower limit of quantification was 10 and 100 lg/L for plasma and urine samples respectively.Results: Sixteen subjects (8 female, 8 male) were included. Population characteristics such as: age ranged from 23 to 50 years (mean ± SD: 38 ± 9.2 years), weight ranged from 51 to 90 Kg (mean ± SD = 64.6 ± 10.1 Kg) and body mass index (BMI) ranged from 19.9 to 24.2 Kg/m 2 (mean ± SD = 21.9 ± 1.5 Kg/m 2 ;). Secnidazole exposure achieved a maximal concentration (Cmax) with a mean of 37.9 ± 8.5 mg/L (range 20–56 mg/L) and at a median time associated with the Cmax (Tmax) of 6 h (range 3–6 h). The area under the curve to the last measurable time (AUC0_t) and the total area under the curve (AUC0_¥) were 1281.9 ± 416.4 mg h/L and 1304.2 ± 444.1 mg h/L (mean ± SD) respectively.The Cl/F and V/F were 1.7 ± 0.5 L/h and 40.2 ± 9.2 L respectively and the elimination half-life (t1/2) was 17.5 ± 4.3 h (mean ± SD). The mean amount of secnidazole excreted in the 168-h urine collection was 310.47 mg (15.5% of the administered dose). For example, for the subject number 5, the observed parameters are: Cmax 37.3 mg/L, Tmax 3 h, AUC0_¥ 1029.5 mg h/L and t1/2 15.6 h.Conclusion: After a 2 g single oral dose, secnidazole presents a good absorption profile and relatively long elimination half life ensuring probable sufficient exposure with once a day administration.

Published
2010

37. Eczéma de contact au diméthylfumarate : intérêt de l'analyse toxicologique

Author

Bretaudeau, M., Avenel-Audran, M., Laurence, Lagarce, Lelièvre, Bénédicte, Turcant, Alain, Département de Pharmacologie-Toxicologie [CHU Angers], Centre Hospitalier Universitaire d'Angers (CHU Angers), PRES Université Nantes Angers Le Mans (UNAM)-PRES Université Nantes Angers Le Mans (UNAM), Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), and Université d'Angers (UA)

Subjects
[SDV]Life Sciences [q-bio]
Abstract

Date du colloque: 10/2009

Published
2009

40. Usage abusif de benfluorex

Author

Cherel, A., Perroux, D., Auclair, V., Courtecuisse, A., Turcant, Alain, Roberge, C., Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), and Université d'Angers (UA)

Subjects
[SDV]Life Sciences [q-bio]
Abstract

Date du colloque: 01/2009

Published
2009

41. Pharmacokinetic analysis of diazepam liberation from avizafone in healthy volunteers : Non-compartmental approach and compartmental modeling

Author

Abbara, Chadi, Lelièvre, Bénédicte, Rousseau, J.-M., Comets, Emmanualle, Bardot, Isabelle, Turcant, Alain, Diquet, Bertrand, Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), Université d'Angers (UA), Génie industriel alimentaire (GENIAL), and Institut National de la Recherche Agronomique (INRA)-Conservatoire National des Arts et Métiers [CNAM] (CNAM)-Institut National Agronomique Paris-Grignon (INA P-G)-Ecole Nationale Supérieure des Industries Agricoles et alimentaires

Subjects
[SDV]Life Sciences [q-bio]
Abstract

Date du colloque: 04/2009

Published
2009

43. Pharmacokinetics of secnidazole after single oral dose in healthy volunteers

Author

Diquet, Bertrand, Lelièvre, Bénédicte, Abbara, Chadi, Turcant, Alain, Bergman, J.-F., Simoneau, G., Brauman, M., Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), and Université d'Angers (UA)

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

National audience

Published
2009

48. Imputabilité en toxicologie postmortem : exemple d'un travail sur la pholcodine

Author

Eysseric, H., Saviuc, P., Gaulier, Jean-Michel, Pépin, G., Dumestre-Toulet, V., Millan, N., Bevalot, F., Alvarez, J.-C., Saussereau, E., Ghysel, M.-H., Turcant, Alain, Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), and Université d'Angers (UA)

Subjects
[SDV]Life Sciences [q-bio]
Abstract

Date du colloque: 10/2008

Published
2008

49. Involvement of pholcodine in the cause of death in 127 forensic cases in France

Author

Eysseric, H., Saviuc, P., Gaulier, Jean-Michel, Pépin, G., Dumestre-Toulet, V., Millan, N., Bevalot, F., Alvarez, J.-C., Saussereau, E., Ghysel, M.-H., Turcant, Alain, Service de Pharmacologie, toxicologie et pharmacovigilance [CHU Limoges], CHU Limoges, Groupe Hospitalier du Havre, Groupe d'Étude des Interactions Hôte-Pathogène (GEIHP), and Université d'Angers (UA)

Subjects
[SDV]Life Sciences [q-bio]
Abstract

Date du colloque: 2008

Published
2008

50. New evidence for oxetorone toxicity.

Author

Deguigne, Marie, Bruneau, Chloé, Touré, Ali, Turcant, Alain, and Le Roux, Gaël

Subjects
SEROTONIN, VENTRICULAR tachycardia, HYPOTENSION, CARDIOGENIC shock, SERUM
Abstract

Context:Oxetorone is a serotonin antagonist antimigraine drug but literature relating to its toxic properties is poor. The aim of this study is to describe the toxicological profile of oxetorone and to highlight any relationship between clinical and analytical findings. Materials and methods:This is a retrospective and observational study of cases exposure to oxetorone, reported to the Angers Poison and Toxicovigilance Centre between January 2002 and May 2016. Severity was assessed using the Poisoning Severity Score (PSS). Cases where data were incomplete, where oxetorone was deemed not accountable, where clinical signs were linked mainly to a co-ingested drug or where the plasma concentration of oxetorone was negative were all excluded. Results:We included 43 cases of exposure, 31 of whom were suicide attempts. The assumed ingested dose (60–3600 mg) was correlated to severity (rs = 0.45,p = 0.01). Symptoms of moderate severity (PSS2 = drowsiness, hypertonia, myosis, convulsions, arterial hypotension, QRS widening, QTc prolongation) were observed following ingestion of more than 600 mg of oxetorone (median dose =1200 mg) and severe symptoms (PSS 3 = coma, convulsions, QTc prolongation, QRS widening, ventricular tachycardia, arterial hypotension, cardiogenic shock) were observed starting from 1800 mg (median dose =2700 mg). In four cases, a secondary worsening of symptoms 10–48 h following ingestion was observed. Plasma oxetorone was measured in four patients. Severe symptoms were observed in the event of a concentration over 0.3 mg/L and the highest measured serum oxetorone level was delayed by 20–48 h following the ingestion for two cases. Conclusions:Several clinical and paraclinical parameters strongly point towards membrane-stabilising properties of the molecule and the risk of a delayed occurrence of symptoms or a secondary worsening. [ABSTRACT FROM PUBLISHER]

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results